L6545
Letrozole
≥98% (HPLC), powder, non-steroidal aromatase inhibitor
Sinonimo/i:
4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
10 MG
105,00 €
50 MG
401,00 €
105,00 €
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C17H11N5
Numero CAS:
Peso molecolare:
285.30
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Vai a
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiNome del prodotto
Letrozole, ≥98% (HPLC)
SMILES string
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: >50 mg/mL
originator
Novartis
storage temp.
2-8°C
Quality Level
Gene Information
human ... CYP19A1(1588)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Categorie correlate
1 of 4
Questo articolo | PHR1540 | BP1234 | 1356971 |
|---|---|---|---|
| assay ≥98% (HPLC) | assay - | assay - | assay - |
| form powder | form - | form powder | form - |
| Quality Level 100 | Quality Level 300 | Quality Level 100 | Quality Level - |
| storage temp. 2-8°C | storage temp. 2-30°C | storage temp. 2-8°C | storage temp. - |
| solubility DMSO: >50 mg/mL | solubility - | solubility - | solubility - |
| color white to off-white | color - | color - | color - |
Application
Letrozole has been used:
- in organoid growth assay to determine its inhibitory capacity(48)
- to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
- to determine its effects on tumor-induced hyperalgesia(50)
- for hormonal manipulation in rats(51)
- to study its effects on lipocalin-2 (Lcn2)(52)
- to determine its effects on mechanical hyperalgesia and aromatase expression(53)
Biochem/physiol Actions
Letrozole acts as an adjuvant agent and is used to treat breast cancer.[1]
Letrozole is a non-steroidal aromatase inhibitor.
Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2 - STOT RE 2
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Drugs for Pregnant and Lactating Women E-Book (2009)
Zahra Shaaban et al.
Iranian journal of basic medical sciences, 25(1), 110-120 (2022-06-04)
Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce. The intrauterine hyperandrogenic environment may underlie changes at the level of hypothalamus, pituitary, ovary
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Israel Ortega et al.
Fertility and sterility, 99(3), 889-896 (2012-12-04)
To evaluate the effects of letrozole on ovarian size and steroidogenesis in vivo, as well as on proliferation and steroidogenesis of theca-interstitial cells alone and in coculture with granulosa cells using an in vitro model. In vivo and in vitro studies. Research laboratory. Immature
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica